Insulatard, flexpen

ApprovedSmall molecule

GGöteborg University

Insulatard, flexpen is one of 30 small molecule programs targeting Cachexia. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

CachexiaActive, not recruiting

CachexiaApproved

Active, not recruiting

Competition

Competitive Landscape

41 competitors in Cachexia

#DrugCompanyPhaseTrials

Taxotere

Advil

2 3

Remicade

OOrganon and Co

Phase 3

1 4

Enbrel

ENBREL

1 6

Kanglaite

ZZhejiang Kanglaite Pharmaceutical Co.Ltd

Approved

2 7

Actos

Takeda

Phase 2

1 8

Jakafi

Incyte

Phase 2

1 9

Beyfortus

BeiGene

Phase 2

1 10

Nano-Crystalline Megestrol Acetate

Changchun GeneScience Pharmaceutical Co., Ltd.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Cachexia1 trial

Insulin Treatment in Cancer Cachexia

Completed·GGöteborg University·Phase 4·NCT00329615·135 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Insulatard, flexpen. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Insulatard, flexpen compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Insulatard, flexpen. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Göteborg University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: GGöteborg University

Insulatard, flexpen

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Cachexia1 trial

References

Drug Info

Quick Facts

Related News